Citius Pharmaceuticals Stock (NASDAQ:CTXR)
Previous Close
$2.60
52W Range
$2.44 - $26.75
50D Avg
$6.51
200D Avg
$14.50
Market Cap
$22.49M
Avg Vol (3M)
$228.76K
Beta
1.66
Div Yield
-
CTXR Company Profile
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
CTXR Performance
Peer Comparison
Ticker | Company |
---|---|
LXRX | Lexicon Pharmaceuticals, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
HOOK | HOOKIPA Pharma Inc. |
FBIO | Fortress Biotech, Inc. |
MCRB | Seres Therapeutics, Inc. |
INZY | Inozyme Pharma, Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
IBRX | ImmunityBio, Inc. |
MREO | Mereo BioPharma Group plc |
BLRX | BioLineRx Ltd. |
ARDX | Ardelyx, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
TERN | Terns Pharmaceuticals, Inc. |
EYEN | Eyenovia, Inc. |